BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of January 14, 2026, BCTX stock price declined to $4.86 with 3,024,897 million shares trading.

BCTX has a beta of 1.35, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.03 to the broad based SPY ETF.

BCTX has a market cap of $9.16 million. This is considered a Sub-Micro Cap stock.

Last quarter Briacell Therapeutics Corp. - Common Shares reported $0 in Revenue and -$4.35 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.07.

In the last 3 years, BCTX traded as high as $1,214.99 and as low as $4.75.

BCTX has underperformed the market in the last year with a price return of -91.7% while the SPY ETF gained +19.8%. BCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -57.4% and -31.6%, respectively, while the SPY returned +4.5% and +1.2%, respectively.

BCTX support price is $9.69 and resistance is $12.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.